Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing

被引：3

作者：

Slade, Michael J. ^{[1
]}

Ghasemi, Reza ^{[1
]}

O'Laughlin, Michelle ^{[2
]}

Burton, Tasha ^{[1
]}

Fulton, Robert S. ^{[2
]}

Abel, Haley J. ^{[1
]}

Duncavage, Eric J. ^{[3
]}

Ley, Timothy J. ^{[1
]}

Jacoby, Meagan A. ^{[1
]}

Spencer, David H. ^{[1
,2
,3
,4
]}

机构：

[1] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA

[2] Washington Univ Sch Med, McDonnell Genome Inst, St Louis, MO USA

[3] Washington Univ Sch Med, Dept Pathol & Immunol, St Louis, MO USA

[4] Washington Univ Sch Med, Dept Med, Div Oncol, St. Louis, MO 63110 USA

来源：

JCO PRECISION ONCOLOGY | 2023年 / 7卷

基金：

美国国家卫生研究院;

关键词：

ACUTE MYELOID-LEUKEMIA; MINIMAL RESIDUAL DISEASE; CLONAL HEMATOPOIESIS; INDUCTION CHEMOTHERAPY; COMPLETE REMISSION; MUTATIONS; DIAGNOSIS; RISK; RECOMMENDATIONS; EVOLUTION;

D O I：

10.1200/PO.22.00559

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE Persistent molecular disease (PMD) after induction chemotherapy predicts relapse in AML. In this study, we used whole-exome sequencing (WES) and targeted error-corrected sequencing to assess the frequency and mutational patterns of PMD in 30 patients with AML. MATERIALS AND METHODS The study cohort included 30 patients with adult AML younger than 65 years who were uniformly treated with standard induction chemotherapy. Tumor/normal WES was performed for all patients at presentation. PMD analysis was evaluated in bone marrow samples obtained during clinicopathologic remission using repeat WES and analysis of patient-specific mutations and error-corrected sequencing of 40 recurrently mutated AML genes (MyeloSeq). RESULTS WES for patient-specific mutations detected PMD in 63% of patients (19/30) using a minimum variant allele fraction (VAF) of 2.5%. In comparison, MyeloSeq identified persistent mutations above 0.1% VAF in 77% of patients (23/30). PMD was usually present at relatively high levels (>2.5% VAFs), such that WES and MyeloSeq agreed for 73% of patients despite differences in detection limits. Mutations in DNMT3A, ASXL1, and TET2 (ie, DTA mutations) were persistent in 16 of 17 patients, but WES also detected non-DTA mutations in 14 of these patients, which for some patients distinguished residual AML cells from clonal hematopoiesis. Surprisingly, MyeloSeq detected additional variants not identified at presentation in 73% of patients that were consistent with new clonal cell populations after chemotherapy. CONCLUSION PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.

引用

页数：13